吉贝尔(688566) - 江苏吉贝尔药业股份有限公司投资者关系活动记录表2024年8月30日

Financial Performance - In the first half of 2024, the company achieved operating revenue of 433.66 million CNY, a year-on-year increase of 3.55% [3] - The net profit attributable to shareholders was 122.01 million CNY, reflecting a year-on-year growth of 26.74% [3] - As of June 30, 2024, total assets amounted to 2.48 billion CNY, up 12.16% year-on-year, while net assets attributable to shareholders reached 2.17 billion CNY, increasing by 13.88% [3] Product Sales - The sales revenue for the main products in the first half of 2024 included: - Likujun tablets: 308.28 million CNY - Nigulol tablets: 65.82 million CNY - Yupingfeng capsules: 20.16 million CNY - Other products: 39.40 million CNY [3] - The sales of Nigulol tablets grew by 90.03% year-on-year, indicating effective promotion and market acceptance [4] Market Position and Product Advantages - Nigulol tablets are positioned as a first-class compound antihypertensive drug, particularly effective for patients with mild to moderate primary hypertension and elevated heart rates [4] - The product has shown significant advantages in clinical settings, with a large market potential due to the prevalence of hypertension combined with high heart rates [4] - Likujun tablets are widely used across various medical departments, maintaining a leading market share in the field of leukocyte elevation drugs [5] Research and Development - The company is advancing its new antidepressant JJH201501, which is currently in Phase III clinical trials, showing promising results in extending drug half-life and improving efficacy [6] - The new anti-tumor drug JJH201601 is undergoing clinical trials, demonstrating superior efficacy compared to existing treatments in preclinical models [6] - The company has developed a deuterated drug technology platform, enhancing drug safety and efficacy while reducing dosage requirements [7] Investor Relations - The company is committed to regular profit distribution, with a mid-term dividend plan under consideration for 2024, based on operational performance [6] - In the first quarter of 2024, the company distributed cash dividends totaling 51.10 million CNY [6]